1-10 of 10
Johanna Rimpiläinen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrating Computational Cytomorphological Analysis of Bone Marrow Smears and Clinical Data for Predicting Response to Venetoclax and Hypomethylating Agents in AML

Henri Sundquist, Mikael Tatun, Mikko Purhonen, Laura Toivanen, Johanna Rimpiläinen, Samuli Rounioja, Timo Siitonen, Marja Pyörälä, Pentti Mäntymaa, Sari Kytölä, Kimmo Porkka, Sanna Siitonen, Heikki Kuusanmäki, Mika Kontro, Oscar E. Brück
Journal: Blood
Blood (2024) 144 (Supplement 1): 4320.
https://doi.org/10.1182/blood-2024-206949
Published: 2024
Journal Articles

Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)

Ida Vänttinen, Joseph Saad, Tanja Ruokoranta, Sari Kytölä, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Caroline A. Heckman, Heikki Kuusanmäki, Mika Kontro
Journal: Blood
Blood (2024) 144 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2024-209429
Published: 2024
Journal Articles

Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Mika Kontro, Anthony S. Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Jenna H Rannikko, Jesper Mickos, Rita Turpin, Milja Hakoniemi, Birge Berns, Sofia Aakko, Inka Pawlitzky, Maija Hollmén, Amer M. Zeidan, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 4265.
https://doi.org/10.1182/blood-2024-206804
Published: 2024
Journal Articles

Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial

Clinical Trials & Observations
Sari Kytölä, Ida Maria Vänttinen, Tanja Ruokoranta, Anu Partanen, Annasofia Holopainen, Joseph Saad, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Katariina Räty, Maija Itälä-Remes, Imre Västrik, Minna Suvela, Alun Owen Parsons, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Tero Jalkanen, Teppo Huttunen, Pia Ettala, MD, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro
Journal: Blood
Blood blood.2024024968.
https://doi.org/10.1182/blood.2024024968
Published: 2024
Includes: Supplemental data
Journal Articles

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Mika Kontro, Anthony Selwyn Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Maija Hollmén, Marie-Louise Fjaellskog, Inka Pawlitzky, Amer M. Zeidan, Naval Daver
Journal: Blood
Blood (2023) 142 (Supplement 1): 2915.
https://doi.org/10.1182/blood-2023-174912
Published: 2023
Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki
Journal: Blood
Blood (2023) 142 (Supplement 1): 2927.
https://doi.org/10.1182/blood-2023-189340
Published: 2023
Journal Articles

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Amanda Ranta, Minna Suvela, Alun Parsons, Imre Västrik, Sanna M. Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro
Journal: Blood
Blood (2022) 140 (Supplement 1): 2020–2022.
https://doi.org/10.1182/blood-2022-159391
Published: 2022
Journal Articles

Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial

Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Amanda Ranta, Tanja Ruokoranta, Annasofia Holopainen, Sirpa Koskela, Milla E.L. Kuusisto, Kimmo Porkka, Riikka Räty, Imre Västrik, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro
Journal: Blood
Blood (2021) 138 (Supplement 1): 228.
https://doi.org/10.1182/blood-2021-147691
Published: 2021
Journal Articles

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Riikka Räty, Tuomo Honkanen, Esa Jantunen, MDPhD, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Outi Kuittinen, Minna Lehto, Maija Mikkola, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, MD, Sanna Siitonen, Merja Suominen, MD, Mirja Vapaatalo, Erkki Elonen
Journal: Blood
Blood (2014) 124 (21): 1749.
https://doi.org/10.1182/blood.V124.21.1749.1749
Published: 2014
Journal Articles

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Clinical Trials & Observations
Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán, Johanna Rimpiläinen, Satu Mustjoki, Richard Smykla, Robert Wild, Roger Luo, Montserrat Arnan, Benoit Brethon, Lydia Eccersley, Henrik Hjorth-Hansen, Martin Höglund, Hana Klamova, Håvar Knutsen, Suhag Parikh, Emmanuel Raffoux, Franz Gruber, Finella Brito-Babapulle, Hervé Dombret, Rafael F. Duarte, Erkki Elonen, Ron Paquette, C. Michel Zwaan, Francis Y. F. Lee
Journal: Blood
Blood (2008) 112 (4): 1005–1012.
https://doi.org/10.1182/blood-2008-02-140665
Published: 2008
Includes: Supplemental data